Organon & Co. (NYSE:OGN) Hits New 1-Year Low – Should You Sell?

Organon & Co. (NYSE:OGN) reached a new 52-week low on Tuesday . The stock traded as low as $10.45 and last traded at $10.67, with a volume of 4492118 shares trading hands. The stock had previously closed at $11.12.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Morgan Stanley dropped their target price on Organon & Co. from $16.00 to $15.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 9th. TD Cowen upgraded Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. Finally, Barclays lowered their target price on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. One analyst has rated the stock with a sell rating, three have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $20.60.

Organon & Co. Stock Performance

The firm has a market capitalization of $2.96 billion, a PE ratio of 3.45, a P/E/G ratio of 0.90 and a beta of 0.73. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. The business has a 50-day simple moving average of $13.99 and a 200-day simple moving average of $15.27.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The firm had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.57 billion. Equities research analysts expect that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 13th. Stockholders of record on Monday, February 24th were given a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a dividend yield of 9.75%. The ex-dividend date was Monday, February 24th. Organon & Co.’s dividend payout ratio (DPR) is presently 33.63%.

Institutional Investors Weigh In On Organon & Co.

A number of institutional investors and hedge funds have recently bought and sold shares of OGN. MassMutual Private Wealth & Trust FSB increased its position in Organon & Co. by 32.4% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company’s stock valued at $41,000 after purchasing an additional 672 shares during the period. Treasurer of the State of North Carolina raised its stake in Organon & Co. by 0.6% in the 4th quarter. Treasurer of the State of North Carolina now owns 113,120 shares of the company’s stock worth $1,688,000 after acquiring an additional 710 shares during the last quarter. Beam Wealth Advisors Inc. raised its stake in shares of Organon & Co. by 3.9% in the fourth quarter. Beam Wealth Advisors Inc. now owns 18,888 shares of the company’s stock worth $282,000 after purchasing an additional 717 shares during the last quarter. HighTower Advisors LLC raised its position in Organon & Co. by 0.5% during the 4th quarter. HighTower Advisors LLC now owns 163,440 shares of the company’s stock worth $2,439,000 after buying an additional 855 shares during the last quarter. Finally, CIBC Asset Management Inc lifted its position in Organon & Co. by 4.9% during the fourth quarter. CIBC Asset Management Inc now owns 25,523 shares of the company’s stock valued at $381,000 after purchasing an additional 1,184 shares during the period. 77.43% of the stock is owned by institutional investors.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.